Objective
Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but less progress has been made in translating findings from in vitro and animal models into effective clinical interventions. INNODIA aims to achieve a breakthrough in the way in which we study T1D to enable us to move closer towards prevention and cure of T1D. To this end, INNODIA joins together the leading European experts from the fields of basic and clinical T1D research, four leading pharmaceutical companies with strong expertise in the discovery and development of diabetes medicines and the two leading public organizations involved in T1D research into one comprehensive collaborative consortium. The clinicians in INNODIA oversee T1D registries and have access to large populations of children and adults with T1D and family members at increased risk of developing the disease. The basic science researchers are experts in beta-cell pathophysiology, immunology, biomarker discovery, bioinformatics, systems biology and clinical trial design. INNODIA will accelerate understanding of T1D through coordinated studies of unique clinical samples and translation-oriented preclinical models. This should deliver novel biomarkers and interventions for testing in appropriately designed trials, to be developed in active collaboration with regulators and patients. INNODIA provides access to unique historical biorepositories and will create the Clinical Sample Network, a clinical EU infrastructure to recruit T1D subjects at diagnosis and at-risk relatives. These individuals will be deep-phenotyped and will provide biosamples, allowing the establishment of a ‘living biobank’ of subjects consented for recall. They will be characterized using standardized clinical, genetic and metabolic phenotyping procedures, including prospective, longitudinal sample collection to facilitate novel biomarker discovery. Diverse biological samples (blood, plasma, serum, urine, stools, etc.) will be collected at
Fields of science
Not validated
Not validated
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
3000 Leuven
Belgium
See on map
Participants (43)
CB2 1TN Cambridge
See on map
8010 Graz
See on map
1050 Bruxelles / Brussel
See on map
1165 Kobenhavn
See on map
3400 Hillerod
See on map
75654 Paris
See on map
00014 HELSINGIN YLIOPISTO
See on map
90014 Oulu
See on map
20014 Turku
See on map
30173 Hannover
See on map
85764 Neuherberg
See on map
01069 Dresden
See on map
89081 Ulm
See on map
53100 Siena
See on map
66013 Chieti
See on map
56126 Pisa
See on map
1210 Luxembourg
See on map
Participation ended
0313 Oslo
See on map
40 055 Katowice
See on map
1000 Ljubljana
See on map
Participation ended
1015 LAUSANNE
See on map
Participation ended
6525 XZ Nijmegen
See on map
2333 ZA Leiden
See on map
WC2R 2LS London
See on map
Participation ended
SN2 1FL Swindon
See on map
31000 Toulouse
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
65929 Frankfurt Am Main
See on map
2880 Bagsvaerd
See on map
WC1A 1DG LONDON
See on map
RG21 4FA Basingstoke
See on map
10281 NEW YORK
See on map
10169 New York
See on map
0450 Oslo
See on map
OX1 2JD Oxford
See on map
CF24 0DE Cardiff
See on map
20132 Milano
See on map
4056 Basel
See on map
4032 Liège
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
EX4 4QJ Exeter
See on map
22100 Lund
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
291 89 Kristianstad
See on map
00165 Roma
See on map
6525 GA Nijmegen
See on map